» Articles » PMID: 26264246

Colistin-tigecycline Versus Colistin-imipenem-cilastatin Combinations for the Treatment of Acinetobacter Baumannii Ventilator-acquired Pneumonia: a Prognosis Study

Overview
Specialty Critical Care
Date 2015 Aug 13
PMID 26264246
Citations 4
Authors
Affiliations
Soon will be listed here.
Citing Articles

Development of a Weighted-Incidence Syndromic Combination Antibiogram (WISCA) to guide empiric antibiotic treatment for ventilator-associated pneumonia in a Mexican tertiary care university hospital.

Briseno-Ramirez J, Gomez-Quiroz A, Avila-Cardenas B, De Arcos-Jimenez J, Perales-Guerrero L, Andrade-Villanueva J BMC Infect Dis. 2025; 25(1):307.

PMID: 40038606 PMC: 11877913. DOI: 10.1186/s12879-025-10677-0.


Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Infections.

Rafailidis P, Panagopoulos P, Koutserimpas C, Samonis G Antibiotics (Basel). 2024; 13(3).

PMID: 38534696 PMC: 10967523. DOI: 10.3390/antibiotics13030261.


Efficacies of Colistin-Carbapenem versus Colistin-Tigecycline in Critically Ill Patients with CR-GNB-Associated Pneumonia: A Multicenter Observational Study.

Wang S, Yang K, Sheu C, Chen W, Chan M, Feng J Antibiotics (Basel). 2021; 10(9).

PMID: 34572663 PMC: 8467228. DOI: 10.3390/antibiotics10091081.


Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.

Chen Z, Shi X Medicine (Baltimore). 2018; 97(38):e12467.

PMID: 30235740 PMC: 6160260. DOI: 10.1097/MD.0000000000012467.


Efficacy of intravenous tigecycline in patients with complex infections: results from 14 Phase III and Phase IV clinical trials.

Tucker H, Wible M, Gandhi A, Quintana A Infect Drug Resist. 2017; 10:401-417.

PMID: 29138583 PMC: 5679678. DOI: 10.2147/IDR.S143306.

References
1.
Freire A, Melnyk V, Kim M, Datsenko O, Dzyublik O, Glumcher F . Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010; 68(2):140-51. DOI: 10.1016/j.diagmicrobio.2010.05.012. View

2.
Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I . Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009; 53(8):3430-6. PMC: 2715599. DOI: 10.1128/AAC.01361-08. View

3.
Bassetti M, De Waele J, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F . Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015; 41(5):776-95. PMC: 7080151. DOI: 10.1007/s00134-015-3719-z. View

4.
Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein J, Welte T . Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009; 34(1):101-2. DOI: 10.1016/j.ijantimicag.2009.01.015. View

5.
Scheetz M, Qi C, Warren J, Postelnick M, Zembower T, Obias A . In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(5):1621-6. PMC: 1855572. DOI: 10.1128/AAC.01099-06. View